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ABSTRACT 
Background: Adiponectin is an anti-inflammatory adipokine and may play a role in 
COPD pathogenesis. This study was to investigate the relationship between 
adiponectin, interleukin (IL)-6, IL-8 and C-reactive protein (CRP) and COPD by 
evaluating these biomarkers in ever-smokers with or without the disease.  
Method: Plasma levels of adiponectin, IL-6, IL-8 and CRP were measured using 
commercial available kits respectively in COPD patients (n=71), healthy 
ever-smokers (n = 62) and non-smokers (n = 51).  
Results: There were significant increases in plasma adiponectin, IL-6 and CRP in 
COPD patients [median (IQR): 4.39 μg/ml (2.68-6.98 μg/ml), 4.19 pg/ml 
(<2.40-6.40 pg/ml), 8.75 mg/l (4.26-40.63 mg/l) respectively] compared to healthy 
ever-smokers [1.90 μg/ml (0.86-2.86 μg/ml), <2.40 pg/ml (<2.40-2.77 pg/ml), 3.71 
mg/l (1.97-10.37 mg/l) respectively; p < 0.001] and non-smokers [1.76 μg/ml 
(1.34-2.52 μg/ml), <2.40 pg/ml (<2.40-2.78 pg/ml), 3.12 mg/l (2.11-5.71 mg/l) 
respectively; p < 0.001]. COPD patients had lower plasma IL-8 levels than healthy 
ever-smokers. Among ever-smokers with or without COPD, plasma adiponectin, 
IL-6 and CRP levels were inversely correlated with FEV1 (% predicted) after 
adjustment for age, BMI, smoking status and pack-years.  
Conclusion: Our findings suggest that in COPD patients, adiponectin might be 
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associated with COPD pathogenesis.  
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Chronic obstructive pulmonary disease (COPD) is a major global disease and 
has been estimated to be the third leading cause of mortality worldwide by 2020.1 It 
is a disease characterized by slowly progressive airflow limitation and includes both 
emphysema and chronic bronchitis.2 Cigarette smoking is the most important risk 
factor, contributing to more than 90% of COPD cases.3 There is increasing evidence 
of systemic inflammation in patients with COPD. However, the main cause for the 
presence of systemic inflammation in COPD patients is still unclear but systemic 
hypoxia due to the progression of COPD has been suggested to be a possibility. 
Several disease biomarkers have been found to be helpful in assessing systemic and 
local inflammation including interleukin (IL)-6, IL-8 and C-reactive protein 
(CRP).4-8
Adiponectin is a secretary 30kD protein synthesized by adipocytes in healthy 
subjects. Three isoforms (trimer, hexamer and high molecular weight complex) were 
found in the circulation with different biochemical properties.9 Its role in 
inflammation is controversial since its plasma concentration decreases in diseases 
such as metabolic syndrome and type II diabetes10 but increases in some 
inflammatory diseases like rheumatoid arthritis and systemic lupus 
erythematosus.11,12 Elevation of plasma adiponectin level was found in patients with 
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stable and acute exacerbation of COPD.13,14 However, in one study, adiponectin was 
found to suppress TNF-α and MMP-12 production in alveolar macrophages and 
absence of adiponectin led to an emphysema-like lesion in adiponectin knock-out 
mice.
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In this study, we hypothesized that circulating levels of adiponectin and other 
conventional inflammatory biomarkers might be associated with lung function in 
ever-smokers with or without COPD. Thus, we studied patients with stable COPD 
who were ever-smokers, and healthy ever-smokers and non-smokers as controls to 
investigate circulating levels of adiponectin, IL-6, IL-8 and CRP, and the 
correlations between these biomarkers and lung functions. 
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Study Subjects 
Three groups of men, a total of 184, were randomly chosen from our 
database of the COPD study conducted by the COPD Study Group of the Hong 
Kong Thoracic Society between 2005 and 2006:16 (1) healthy life long non-smokers; 
(2) healthy ever-smokers: either current smokers or ex-smokers (defined as those 
who had not smoked within the last 12 months) with FEV1/FVC ≥ 70 and FEV1 ≥ 80 
(% predicted), and no chronic respiratory symptoms; and (3) stable COPD patients, 
who are ever-smokers and defined as FEV1/FVC < 70 and/or FEV1 < 80 (% 
predicted) according to the diagnostic criteria of Global Initiative for Chronic 
Obstructive Lung Disease (GOLD).17 Stable COPD patients were defined as those 
who did not have exacerbation within the last 12 weeks prior to recruitment. The 
healthy subjects, irrespective of smoking habits, were recruited from those attending 
churches and community centers for the elderly across Hong Kong. COPD patients 
were recruited from outpatient respiratory clinics. Lung function tests were 
performed in all control subjects and patients using standardized methods according 
to the American Thoracic Society guidelines.18 The predicted values were based on 
reference values obtained from our local population.19 Information about smoking 
habits, respiratory symptoms and other diseases such as cardiovascular diseases 
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were obtained from a detailed questionnaire. Subjects were excluded if they had a 
history of asthma or other lung illnesses. Four of the COPD patients had coronary 
artery disease. There was no patient from our cohort had stage 1 disease [FEV
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1/FVC 
< 70, FEV1 ≥ 80 (% predicted)] and were subdivided into three groups according to 
disease severity based on GOLD criteria (stage 2: 50% ≤ FEV1 < 80% predicted; 
stage 3: 30% ≤ FEV1 < 50% predicted; stage 4: FEV1 < 30% predicted).16 Patients 
were also subdivided into two groups based on body mass index (BMI):  BMI < 
18.5 kg/m2 and BMI ≥ 18.5 kg/m2 according to WHO criteria.20 Every participant 
signed the informed consent form and this study was approved by the Ethics 
Committee of The University of Hong Kong.  
 
Blood Sampling and Analysis 
Venous blood samples were taken from all subjects, centrifuged immediately 
at 1600x g for 10 min at 4°C and stored at -70°C. Plasma adiponectin (R&D 
Systems Inc., MN, USA), IL-6, IL-8 ((BD Biosciences Pharmingen, San Diego, CA, 
USA) and CRP (Diagnostic Systems Laboratories Inc., Texas, USA) were measured 
by commercially available enzyme-linked immunosorbent assay (ELISA) kits 
respectively.   
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Statistical Analysis 68 
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Data were expressed as mean ± SD or median (interquartile range; IQR) for 
normally or non-normally distributed variables, respectively, unless specified. The 
normality was tested by the method of Kolmogorov-Smirnov. Demographic data 
were compared between any two groups by either Student t test or χ2 statistics. 
Plasma levels of adiponectin, IL-6, IL-8 and CRP were compared by Mann-Whitney 
U test. All data including those whose readings were below the detection limit were 
included in these comparisons. In COPD patients and healthy ever-smokers, the 
relationships between adiponectin, IL-6, IL-8 or CRP and the lung function 
measures or other demographic variables were first investigated by the Spearman 
rank-order correlation using data from all subjects. If similar results were obtained 
by the Pearson product-moment correlation, the Pearson partial correlation between 
log-transformed adiponectin, IL-6, IL-8 or CRP and the lung function measures with 
adjustment for cofounders was then estimated using data from those with positive 
values. Multiple linear regression analyses were performed to study the relationships 
between COPD severity and plasma adiponectin, IL-6, IL-8 or CRP (in log scale), 
adjusting for age, BMI, smoking status and pack-years smoked within COPD 
patients only. Stages 2, 3 and 4 COPD patients were coded with values 1, 2 and 3, 
respectively, and entered the regression model as a continuous independent factor.  
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All p-values were not adjusted for multiple testing due to the exploratory 
nature of this study. SPSS for Windows version 16.0 statistical package (SPSS, 
Chicago, IL) was used for statistical analyses.   
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Demographic characteristics of the study subjects are summarized in Table 1. 
All the recruited COPD patients were current or ex-smokers. COPD patients were 
significantly older and had a significantly lower BMI than healthy non-smokers or 
ever-smokers. COPD patients also had higher pack-year smoked than healthy 
ever-smokers. There were 5 missing values for pack-years smoked due to 
incomplete information in the questionnaire. As expected, there were significant 
reductions of FEV1 (% predicted), FVC (% predicted) and FEV1/FVC ratio in 
COPD patients compared with healthy ever-smokers, irrespective of smoking status. 
Plasma adiponectin, IL-6 and CRP levels were significantly elevated in COPD 
patients compared with healthy ever-smokers or non-smokers. Plasma IL-8 levels 
were significantly increased in COPD patients and healthy ever-smokers compared 
with healthy non-smokers. Healthy ever-smokers also had higher levels of plasma 
IL-8 compared with healthy non-smokers while COPD patients had lower plasma 
IL-8 levels than healthy ever-smokers (Table 2).  
In ever-smokers with or without COPD, Spearman’s correlation analysis did 
not show pair-wise correlations among plasma adiponectin, IL-8 and CRP (r < 0.18 
and p > 0.05). However, plasma IL-6 showed pair-wise correlations with adiponectin 
and CRP (r = 0.374 and 0.284 respectively, p < 0.01). Plasma adiponectin and IL-6 
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was found to have positive correlations with age (r = 0.424 and 0.303 respectively, p 
≤ 0.001) and pack-year smoked (r = 0.254 and 0.338 respectively, p < 0.01) and 
inverse correlation with BMI (r = -0.623 and -0.396, p < 0.001). After controlling for 
age, BMI, smoking status and pack-year smoked, plasma IL-6 remained positively 
correlated with plasma CRP (r = 0.356, p < 0.001). Ex-smokers regardless of lung 
function status also had higher plasma adiponectin levels than current smokers 
(median: 3.26, IQR: 1.96-5.65 μg/ml versus median: 2.24, IQR: 1.03-4.43 μg/ml, p = 
0.016, Mann-Whitney U test).  
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Pulmonary function parameters, FEV1 (% predicted), FVC (% predicted) and 
FEV1/FVC ratio, correlated negatively with plasma adiponectin, IL-6 and CRP but 
positively with plasma IL-8 (data not shown). After controlling for age, BMI, 
smoking status and pack-year smoked, these lung function parameters remained 
inversely correlated with plasma adiponectin, IL-6 and CRP levels, and positively 
correlated with plasma IL-8 levels (Table 3).  
There were no significant differences in age, BMI and pack years smoked 
among COPD patients according to disease severity (data not shown). We found an 
increase in plasma adiponectin and CRP levels with disease severity (Figure 1A and 
1D). Stage 4 COPD patients had the highest median of plasma adiponectin levels 
compared to stage 2 and stage 3 COPD patients. No difference was found in plasma 
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IL-6 among different stages (Figure 1B). Plasma IL-8 levels show a non-significant 
decrease with disease severity (Figure 1C). 
The COPD patients with BMI < 18.5 kg/m2 had significantly elevated 
plasma adiponectin levels in comparison to those with BMI ≥ 18.5 kg/m2 (Figure 
2A). They also showed higher median of plasma IL-6 and IL-8, and lower CRP 
levels than COPD patients with BMI ≥ 18.5 kg/m2 but not reaching statistical 
significance (Figure 2B-D). 
After adjusting for age, BMI, smoking status and pack-year smoked, 
multiple linear regression analyses showed that plasma adiponectin levels still 
increased with the COPD staging (Table 4) but plasma IL-6, IL-8 or CRP levels 
were not related to COPD staging.   
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In this study, we found that COPD patients who were ever-smokers had 
significantly higher plasma levels of adiponectin, IL-6 and CRP than healthy 
ever-smokers and non-smokers. Plasma levels of adiponectin, IL-6 and CRP were 
negatively correlated with FEV1 (% predicted) in COPD patients and healthy 
ever-smokers.  
Our findings that COPD patients had a significantly higher plasma 
adiponectin levels and that the more severe COPD patients had even higher levels 
suggest that adiponectin might be inappropriately secreted in this disease. The exact 
role of adiponectin could not be elucidated in this study since it is a cross-sectional 
study. In contrast to our findings, Tomoda et al13 and Kirdar et al14 observed no 
relationship between lung function and plasma adiponectin. This may probably be 
due to the limited sample size in their studies. Although the function of adiponectin 
remains controversial, adiponectin was recently found positively correlated with 
IL-6 in dialysis patients21, in line with our findings. Additionally, we found that 
plasma adiponectin levels were inversely correlated with BMI in the group of 
healthy ever-smokers and those with COPD as reported in previous studies.13 COPD 
patients with BMI < 18.5 kg/m2 had a significant elevation of circulating 
adiponectin compared to those with BMI ≥ 18.5 kg/m2 as previously reported.13 This 
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could be the consequence of severely decreased body fat as reported in patients with 
anorexia nervosa and cachexia.
158 
159 
160 
161 
162 
163 
164 
165 
166 
167 
168 
169 
170 
171 
172 
173 
174 
175 
176 
22,23 
We demonstrated elevated plasma IL-8 levels in ever-smokers with or 
without COPD compared with those of healthy non-smokers; but COPD patients 
had lower plasma IL-8 levels than healthy ever-smokers. Our results are in contrast 
to that of previous researchers who found marginally higher plasma IL-8 levels in 
COPD patients compared with those of healthy smokers24, and elevated IL-8 levels 
in induced sputum of COPD patients.25,26 This discrepancy might be explained by 
the fact that local and systemic inflammations are differentially regulated.27 In 
studies done by Yoshikawa et al28, chemotactic activity and migration of neutrophils 
from blood of severe COPD patients were lower than that of less severe patients or 
healthy smokers. Fietta and colleagues29 also found that the number of functional 
neutrophils and monocytes was reduced in chronic bronchitis. Our finding of 
reduced plasma IL-8 levels in more severe COPD patients suggests that a reduction 
of chemoattractant might be present in severe COPD cases. Another possible 
explanation is that the release of IL-8 is suppressed by an endogenous inhibitor 
which could be adiponectin as adiponectin has been found to inhibit IL-8 
production.30 Moreover, IL-8 might also be suppressed by CRP as reported by an in 
vitro study.31
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Ever-smokers with COPD had the highest plasma IL-6 and CRP levels 
compared with those of healthy non-smokers and ever-smokers, in line with 
previous publications.
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7,32,33 FEV1 (% predicted) was found to be inversely correlated 
to plasma IL-6 and CRP levels as in previous report,8,32 suggesting that systemic 
inflammation might play a role in the development of airway obstruction. Plasma 
IL-6 also showed a positive correlation with CRP, which is consistent with previous 
findings,32 since IL-6 is a positive regulator of CRP by triggering acute-phase 
response in liver.34 
The strength of our study is that we have investigated the potential role of 
adiponectin alongside that of other inflammatory biomarkers (IL-6, IL-8 and CRP) 
in relation to the lung function in the same subjects with a larger sample compared 
with previous studies.13,14 In addition, we have used all-male study population to 
avoid the sex differences in the plasma levels of different forms of adiponectin9 and 
the disease state of emphysema due to a heterogeneous population.35 However, the 
sample size is still relatively small for subgroup analysis after stratification by 
disease severity but this is the first study to demonstrate the relationship between 
plasma adiponectin and COPD severity. Our study also has several limitations. 
Firstly, this is a cross-sectional study that limits the interpretation of a causal link 
between the markers adiponectin, IL-6, IL-8 and CRP, and lung function changes. 
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As reported by Summer and coworkers,15 mice deficient in adiponectin was more 
susceptible to develop emphysema, which implied that adiponectin might be 
involved in tissue repair rather than disease development. However, there are no 
association studies for adiponectin gene polymorphisms and COPD in determining 
which polymorphism causes the functional effect. Prospective studies in smokers 
with or without COPD are required to fully address the role of adiponectin in the 
development and progression of COPD. Secondly, we carried out the measurements 
in plasma, which reflects only systemic changes and may not adequately reflect the 
local concentrations in the lungs. Further studies involving biological samples such 
as BAL, induced sputum and exhaled breath condensate, might shed more light 
locally. Thirdly, we measured total adiponectin levels in plasma instead of its 
different isoforms in the present samples. High molecular weight (HMW) isoform 
was found to have greater clinical significance than the other two isoforms in 
obesity-related diseases.
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36 A similar pattern of total adiponectin and HMW isoform 
was recently observed with the HMW isoform being the most abundant 
adiponectin.37 In this study, we could not rule out whether a specific isoform such as 
HMW isoform involves in COPD progression or not, however, the measurement of 
total adiponectin or a specific isoform in plasma has been demonstrated to produce 
similar results.38
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CONCLUSION 215 
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We found an inverse relationship between FEV1 (% predicted) and plasma 
adiponectin, IL-6 or CRP levels in ever smokers. In COPD patients, we found 
elevated plasma adiponectin, IL-6 and CRP levels and the more severe the disease, 
the higher the adiponectin levels. These findings suggest that these biomarkers 
might be associated with COPD. As this study provides evidence of association 
rather than of causation, prospective studies are required to assess biological 
significance of these associations.
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Table 1. Characteristics of study subjects   
 
Healthy non-smokers
n = 51 
Healthy ever-smokers
n = 62 
COPD 
n = 71 
Age 45 ± 13 56 ± 15# 70 ± 9?,‡
Smoking status 
(current/ex-smoker) 
NA 31/31 19/52ξ
Pack-years smoked NA 23 ± 15 48 ± 34‡
BMI 24.6 ± 3.5 23.7 ± 3.2 20.7 ± 3.7?,‡
FEV1 % predicted 105 ± 14 102 ± 15 37 ± 13?,‡
FVC % predicted 104± 14 102 ± 13 72 ± 21?,‡
FEV1/ FVC 81 ± 5 78 ± 6# 39 ± 9?,‡
Data are expressed as mean ± SD.  
# p < 0.01 between healthy non-smokers and ever-smokers, ? p < 0.001 between healthy 
non-smokers and COPD patients and ‡ p < 0.05 between healthy ever-smokers and COPD 
patients by either t-test or Mann-Whitney U test. 
ξ p = 0.01 by Chi-square test with continuity correction.  
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Table 2. Plasma levels of inflammatory mediators 
 Healthy 
non-smokers 
n = 51 
Healthy ever-smokers 
N = 62 
COPD 
N = 71 
Adiponectin (μg/ml) 1.76 (1.34-2.52) 1.90 (0.86-2.86) 4.39 (2.68-6.98)?,‡
IL-6 (pg/ml) (all) <2.40 (<2.40-2.78) <2.40 (<2.40-2.77) 4.19 (2.67-6.40)?,‡
≥ 2.4* only n = 18 
2.98 (2.75-3.50) 
n = 20 
3.09 (2.77-3.84) 
n = 56 
4.98 (3.61-8.11) 
IL-8 (pg/ml) (all) < 3.10 (<3.10-4.14) 13.84 (6.86-29.73)# 7.26 (3.63-14.25)?,‡
≥ 3.1φ only n = 16 
7.50 (4.31-12.58) 
n = 55 
14.64 (8.35-30.42) 
n = 55 
9.92 (6.30-17.33) 
CRP (mg/l)  3.12 (2.11-5.71) 3.71 (1.97-10.37) 8.75 (4.26-40.63)?,‡
Data are expressed as median (IQR). 
* The detection limit for IL-6 was 2.4 pg/ml. There were 33 healthy non-smokers, 42 healthy 
ever-smokers and 15 COPD patients whose IL-6 was < 2.4 pg/ml. 
φ The detection limit for IL-8 was 3.1 pg/ml. There were 35 healthy non-smokers, 7 
healthy ever-smokers and 16 COPD patients whose IL-8 was < 3.1 pg/ml. 
# p < 0.01 between healthy non-smokers and ever-smokers,? p < 0.001 between healthy 
non-smokers and COPD patients and ‡ p < 0.05 between healthy ever-smokers and COPD 
patients by either t-test or Mann-Whitney U test. 
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Table 3. Relationship between plasma adiponectin, IL-6, IL-8 or CRP and lung 
function parameters in ever-smokers with or without COPD (Pearson partial 
correlation)a  
 Adiponectin IL-6b IL-8c CRP 
FEV1 (% predicted) -0.370*** -0.381*** 0.208* -0.303**
FVC (% predicted) -0.262** -0.189 0.196* -0.187 
FEV1/FVC ratio -0.302** -0.368*** 0.193* -0.284**
*p < 0.05, **p < 0.01 and ***p < 0.001. aadjusted for age, BMI, smoking status and 
pack-years smoked. 
bAll patients with data on smoking status were included, except 21 with negative IL-6 
values. 
cAll patients with data on smoking status were included, except 7 with negative IL-8 
values.  
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 Adiponectin IL-6a IL-8b CRP 
 β# SE* p β# SE* p β# SE* p β# SE* p 
Age 0.004 0.009 0.623 -0.002 0.011 0.874 0.009 0.017 0.593 -0.011 0.024 0.639 
BMI -0.114 0.02 <0.001 -0.047 0.024 0.058 -0.021 0.036 0.556 0.008 0.053 0.884 
Smoking status 0.203 0.175 0.251 -0.121 0.212 0.571 -0.013 0.320 0.968 -0.119 0.464 0.798 
Pack-year smoked -0.002 0.002 0.436 0.003 0.003 0.218 0.002 0.004 0.669 0.002 0.006 0.687 
Disease severity 0.220 0.103 0.037 -0.183 0.131 0.166 -0.237 0.189 0.215 0.210 0.273 0.444 
Table 4. Associations between plasma levels of adiponectin, IL-6, IL-8 or CRP and disease severity in patients with COPD adjusted for age, BMI, 
smoking status and pack-years smoked by multiple linear regression analysis 
a,b All COPD patients with data on smoking status were included, except 6 with negative IL-6 values and 4 with negative IL-8 values.
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#Unstandardized coefficients; *Standard error 
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Figure legends 
Figure 1. Plasma adiponectin, IL-8, IL-6 and CRP levels according to disease severity. 
(A) Plasma adiponectin in stage 2, 3, and 4 COPD patients with n = 14, 35, and 22 
respectively. * p < 0.05  by Mann-Whitney U test. (B) Plasma IL-6 in stage 2, 3, and 
4 COPD patients with n = 11, 33, and 21 respectively. Three negative values from 
stage 2, two negative values from stag 3 and one negative values from stage 4 were 
not included in the plot. (C) Plasma IL-8 in stage 2, 3 and 4 COPD patients with n = 
14, 32, and 21 respectively. Three negative values from stage 3 and one negative 
value from stage 4 were not included in the plot. (D) Plasma CRP in stage 2, 3 and 4 
COPD patients with n = 14, 35 and 22 respectively). The y-axis of plasma CRP was 
restricted to 150 mg/l; one subject from stage 2 (251 mg/l), four subjects from stage 3 
(196, 373, 411 and 551 mg/l) and three subjects from stage 4 (165, 199 and 414 mg/l) 
were not shown in the plot. The horizontal line represents median values. 
 
Figure 2. Plasma levels of adiponectin, IL-8, IL-6 and CRP according to BMI. (A) 
Plasma adiponectin in COPD patients with BMI ≥ 18.5 kg/m2 (n = 49) and BMI < 
18.5 kg/m2 (n = 22). *** p < 0.001 between BMI ≥ 18.5 kg/m2 and BMI < 18.5 kg/m2 
by Mann-Whitney U test. (B) Plasma IL-6 in COPD patients with BMI ≥ 18.5 kg/m2 
(n = 45) and BMI < 18.5 kg/m2 (n = 20). Four negative values from BMI ≥ 18.5 kg/m2 
and two negative values from BMI < 18.5 kg/m2 were not included in the plot. (C) 
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Plasma IL-8 in COPD patients with BMI ≥ 18.5 kg/m2 (n = 45) and BMI < 18.5 kg/m2 
(n = 22). Four negative values from BMI ≥ 18.5 kg/m2 were not included in the plot.  
(D) Plasma CRP in COPD patients with BMI ≥ 18.5 kg/m2 (n = 49) and BMI < 18.5 
kg/m2 (n = 22). The y-axis of plasma CRP was restricted to 150 mg/l; four subjects 
from BMI ≥ 18.5 kg/m2 (196, 199, 441 and 551 mg/l) and four subjects from BMI < 
18.5 kg/m2 (165, 251, 373 and 411 mg/l) were not shown in the plot. The horizontal 
line represents median values.  
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